Catalyst Pharmaceuticals Inc’s filing revealed that its Officer Miller Steve acquired Company’s shares for reported $2.33 million on Aug 26 ’25. In the deal valued at $20.28 per share,115,000 shares were bought.
Then, Daly Richard J bought 22,970 shares, generating $473,641 in total proceeds.
Before that, Sundaram Preethi sold 2,324 shares. Catalyst Pharmaceuticals Inc shares valued at $61,377 were divested by the Chief Strategy Officer at a price of $26.41 per share. As a result of the transaction, Sundaram Preethi now holds 42,681 shares, worth roughly $0.85 million.
Robert W. Baird initiated its Catalyst Pharmaceuticals Inc [CPRX] rating to an Outperform in a research note published on February 04, 2025; the price target was $28. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in mid November with a ‘”an Overweight”‘ rating. Citigroup began covering CPRX with “Buy” recommendation on March 14, 2024. BofA Securities started covering the stock on March 07, 2024. It rated CPRX as “a Buy”.
Price Performance Review of CPRX
On Tuesday, Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] saw its stock fall -3.30% to $19.94. Over the last five days, the stock has lost -1.53%. Catalyst Pharmaceuticals Inc shares have fallen nearly -3.86% since the year began. Nevertheless, the stocks have fallen -4.46% over the past one year. While a 52-week high of $26.58 was reached on 06/09/25, a 52-week low of $19.00 was recorded on 08/07/25.
Levels Of Support And Resistance For CPRX Stock
The 24-hour chart illustrates a support level at 19.60, which if violated will result in even more drops to 19.27. On the upside, there is a resistance level at 20.50. A further resistance level may holdings at 21.07.
How much short interest is there in Catalyst Pharmaceuticals Inc?
A steep rise in short interest was recorded in Catalyst Pharmaceuticals Inc stocks on 2025-08-15, growing by 23703.0 shares to a total of 8.94 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 8.92 million shares. There was a rise of 0.27%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 21, 2023 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $30 price target.
